News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Allows HalcyGen's IND Application – Pivotal US-Based Clinical Trials to Proceed


6/17/2008 4:52:03 PM

MELBOURNE, Australia, June 17, 2008-HalcyGen Pharmaceuticals Limited (ASX:HGN) has received approval from the US Food and Drug Administration (FDA) to begin pivotal pharmacokinetic* (PK) studies in the United States. These studies are the precursor to SUBATM-Itraconazole product registration.

Read at PharmaLive


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES